Oslo, Norway, October 10, 2025 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that 1,200,000 share options have been granted to an employee and primary insider under the company’s share option scheme. The share options will have a strike price of NOK 7.00 per share, vest equally over a four-year vesting period and expire in 2030. 

Please see further details in attached document.
